According to a recent study, the cytofluorimetry results showed a collapse of most lymphocyte populations in COVID patients. As a result, there was a significant production of cytokines, which helps to impair the respiratory inflammation.

The rise in T-helper cell 17 (TH17) and Interleukin (IL)-17 in a group of cases and the confirmation of a major increase of the soluble receptor of IL-17A (IL-17RA) in patients with low severity suggests that the monoclonal antibodies are beneficial in some patients. 

The study was conducted to examine immunocytometric variation in COVID-19. It was seen that the total lymphocytes were decreased in 50-80% of the patients. It was found that in patients with advanced stages the levels of tumor necrosis factor (TNF)-α and IL-17A were high whereas in less severe cases only the IL-17RA levels were at rise.

Mostly, COVID patients suffer a lymphocyte collapse, which is related to the severity of the disease and involve most subpopulations. The treatment with Tocilizumab offered inconsistent outcomes in terms of cytokine decrease and lymphocyte restoration. While the significant rise of TH17 cells and IL-17A/IL-17RA levels was observed in a group of COVID patients.

The study suggested that targeting the IL-17A pathway with the aid of a specific monoclonal antibody can be contributing in a group of COVID patients under the guidance of cytofluorimetric analysis and ILs levels.

Hence, the immunocytometric analysis of COVID patients was found contributing as a personalized therapy.